Objective: To estimate the health impact, financial costs, and cost-effectiveness of scaling-upcoverageofhumanpapillomavirus(HPV)vaccination(younggirls)andcervical cancer screening (women of screening age) for women in countries that will likely need donor assistance. 
| INTRODUCTION
Despite the availability of both primary and secondary prevention, an estimated 528000women worldwide developed cervical cancer in 2012, and 266 000 died from the disease. 1 Primary prevention is available in the form of effective prophylactic vaccines against the oncogenichumanpapillomavirus(HPV)genotypesthatcauseapproximately 70% (bivalent and quadrivalent vaccines) to 90% (9-valent vaccine) of cervical cancers. [2] [3] [4] [5] For women beyond the target age of adolescent vaccination, secondary prevention with screening can detect and treat precancerous lesions caused by oncogenic HPV beforeprogressiontoinvasivecancer.Yettheseopportunitiesforpreventionarenotreachingwomeninpoorcountries,where85%ofthe
cervical cancer burden resides.
TheWHOrecommendsHPVvaccinationforgirlsaged9-13years, prior to initiation of sexual activity. 6 For screening, the WHO 
| METHODS

| Analytic overview
We used a model-based approach to synthesize population, demographic, and epidemiological data from 50 low-and lower-middleincome(LIandLMI)countrieswithpopulationsover1millionpersons
and gross national income (GNI) per capita less than or equal to US $2585 (Supplementary material Tables S1 and S2) from the literature, using previously described methods. 15 We estimatedcountry-specificepidemiologicdatainputsonburdenofHPV, precancer, and cervical cancer by applying previously described meth- Prospects. 24 Eachbirthcohortwastrackedoveritslifetimetocapture health service utilization, burden of disease, and long-term health impactofvaccinationandscreeningduringtheinterventionperiod.
| HPV vaccination and cervical cancer screening strategies
Scale-up assumptions for vaccination and screening are displayed in withnoserotypereplacementandnoherdimmunitybenefit.
The health impact of screening was based on the screening test anditsperformancecharacteristics(SupplementarymaterialTableS6).
Wemadethefollowingsimplifyingassumptionsacrossallcountries:
(1) VIA and HPV testing were followed by cryotherapy for all eligiblewomen,whichwas90%effectiveattreatingHPVinfectionsand
underlyingprecancer; (2) For each screening test, we used the microsimulation model to estimate percent reductions in age-specific cervical cancer incidence andmortality(in5-yearagegroupsfromage20toage84years)attributable to a screening program with the features described above (e.g.
treatmenteffectiveness,eligibilityforcryotherapy,etc).Descriptionsof thismicrosimulationmodelandtheparameterizationprocess(including model calibration to epidemiologic data for the development of four country-specific models reflecting the natural history of cervical cancer in El Salvador, India, Nicaragua, and Uganda) have been previously published. [16] [17] [18] Inbrief,weestimatedbaseline"prior"inputvaluesfor natural history transitions using longitudinal data. [25] [26] [27] [28] To reflect het- 
| Costs
All costs were converted to 2013 US $, and we assumed that inter- We estimated the country-specific HPV vaccine delivery cost per dose as previously described (Supplementary material Tables S10 and   S11 ).
15
Forscreening-relatedcosts,weincludedthecountry-specific direct medical costs associated with screening, diagnosis (if relevant), and treatment of precancer, as previously described (Supplementary   material Tables S12-S14) . 15 Cancer treatment costs were similarly derived for each country, assuming stage-specific treatment protocols based on FIGO guidelines (Supplementary material Tables S15 and S16 ).
| RESULTS
| Health impact
TheaggregatedhealthimpactofHPVvaccinationof10-year-oldgirls andcervicalcancerscreeningofwomenaged35yearsovera10-year Table S18 . As more cancer treatment costs were averted, the net cost perDALYavertedfromHPVvaccinationbecamemoreattractive.The netcostassociatedwithscreeningbecamenegative,asthescreening program costs were lower than the cancer treatment costs averted. As aresult,thenetcostperDALYavertedfromascreeningprogramwas cost saving. JK contributed to the design and planning of the study, and manuscript revisions. SR contributed to the design, planning, and conduct ofthestudy;analyzeddata;anddraftedthemanuscript.
| Cost and cost-effectiveness
| DISCUSSION
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